Prussian Blue Nanozyme Treatment of Ischemic Brain Injury via Reducing Oxidative Stress Inhibits Inflammation, Suppresses Apoptosis, and Promotes Neurological Recovery

Ischemic stroke is one of the leading causes of death and severe disability. The overproduction of reactive oxygen species (ROS) after ischemic injury causes a series of inflammatory reactions, which is considered to be the key factor in aggravating brain injury. However, the current clinical drug treatment effect is not satisfactory. Therefore, ROS scavengers that can remove excess ROS production have great therapeutic potential. Nanoenzymes with potent antioxidant stress and anti-inflammatory properties have the potential to treat ischemic stroke. Herein, we used a Prussian blue nanoenzyme (PBzyme) to study the treatment of ischemic stroke. The comprehensive effects of PBzyme on ROS in vivo and in vitro were investigated. Pbzyme inhibited the activation of macrophages and the release of inflammatory factors in the brain, promoted the polarization of microglia to M2, inhibited neuronal apoptosis, and promoted the recovery of neurological function after ischemic stroke. This research may provide a promising application for nanoenzymes to treat brain diseases.